Gene Edited T Cell Therapies for Inborn Errors of Immunity.

Area of Science:

• Immunology
• Genetics
• Cell Therapy

Background:

• Inborn errors of immunity (IEIs) are inherited immune system disorders with severe phenotypes, affecting 1/1,000-10,000 people.
• Current treatments are often unsatisfactory, and while allogeneic stem cell transplantation is curative, it carries significant risks.
• Gene editing technologies offer precise DNA modification to correct genetic defects, presenting a potential paradigm shift in IEI treatment.

Purpose of the Study:

• To review the advancements in T cell gene therapy and gene editing for inborn errors of immunity.
• To highlight the potential of T cell gene editing as a curative and less toxic alternative to existing therapies.
• To discuss pre-clinical evidence supporting gene editing T cell therapies for IEIs.

Main Methods:

• Review of historical T cell gene therapy and current gene editing developments.
• Focus on CRISPR-based gene editing for precise DNA correction.
• Examination of pre-clinical studies demonstrating proof-of-concept for IEI treatment.

Main Results:

• Gene editing repairs or replaces mutations, unlike gene addition techniques.
• T cell gene editing shows higher efficiency and reduced off-target risks in lymphoid compartment disorders.
• Pre-clinical studies validate gene editing T cell therapies as a viable treatment strategy for specific IEIs.

Conclusions:

• Gene editing T cell therapies hold significant potential for treating inborn errors of immunity.
• This approach may offer a less toxic and curative therapeutic option compared to allogeneic stem cell transplantation.
• Further development of gene edited T cell therapies is crucial for patients with IEIs.